E-viri
PDF
Recenzirano
Odprti dostop
-
Hensley, Matthew K; Bain, William G; Jacobs, Jana; Nambulli, Sham; Parikh, Urvi; Cillo, Anthony; Staines, Brittany; Heaps, Amy; Sobolewski, Michele D; Rennick, Linda J; Macatangay, Bernard J C; Klamar-Blain, Cynthia; Kitsios, Georgios D; Methé, Barbara; Somasundaram, Ashwin; Bruno, Tullia C; Cardello, Carly; Shan, Feng; Workman, Creg; Ray, Prabir; Ray, Anuradha; Lee, Janet; Sethi, Rahil; Schwarzmann, William E; Ladinsky, Mark S; Bjorkman, Pamela J; Vignali, Dario A; Duprex, W Paul; Agha, Mounzer E; Mellors, John W; McCormick, Kevin D; Morris, Alison; Haidar, Ghady
Clinical infectious diseases, 08/2021, Letnik: 73, Številka: 3Journal Article
A chimeric antigen receptor-modified T-cell therapy recipient developed severe coronavirus disease 2019, intractable RNAemia, and viral replication lasting >2 months. Premortem endotracheal aspirate contained >2 × 1010 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA copies/mL and infectious virus. Deep sequencing revealed multiple sequence variants consistent with intrahost virus evolution. SARS-CoV-2 humoral and cell-mediated immunity were minimal. Prolonged transmission from immunosuppressed patients is possible.
